Novel role for α1‐adrenergic receptor subtypes in lower urinary tract symptoms

D. Schwinn

DOI: https://doi.org/10.1046/j.1464-410X.2000.00098.x

2000-10-01

BJU International

Abstract:It has long been appreciated that the pathophysiology underlying BPH and LUTS is complex, involving multiple signal transduction systems and biological in ̄uences [1]. Detrusor hypertrophy is well characterized in BPH and was initially thought to result from BOO and resultant upstream remodelling. Many clinical symptoms associated with BPH re ̄ect pathophysiological changes in the bladder [2]. Because either surgical removal of prostate tissue or pharmacological prostate/bladder neck smooth muscle relaxation relieves BOO and increases urine ̄ow, the initial clinical assumption was that bladder smooth muscle hypertrophy, in ̄ammation, and irritative and associated detrusor instability symptoms, would gradually regress once BOO was relieved. However, this is not always the case, suggesting potentially novel roles for bladder pathophysiology in LUTS (in the presence and absence of BOO). a1-adrenergic receptor (a1AR) antagonists are effective in treating both prostate and bladder pathophysiology in LUTS [2±4]. There are three a1AR subtypes (a1a, a1b, a1d) [5,6], with the role of a1aARmediated human prostate smooth muscle contraction being well documented [7]. a1a-Selective antagonists relax prostate smooth muscle, relieve BOO and enhance urine ̄ow [2±4]. However, a1aAR selective antagonists do not uniformly relieve LUTS [2,8]. Recent evidence from our laboratory suggests a novel role for the a1dAR in mediating bladder symptoms associated with LUTS [9,10]. The present article reviews general a1AR pharmacology as a background to discussing the role of speci®c a1AR subtypes in prostatic and nonprostatic sites potentially important in LUTS.